<DOC>
	<DOCNO>NCT02616601</DOCNO>
	<brief_summary>This study evaluate efficacy safety generic formulation fluorouracil 0.5 % cream brand product ( Carac ) subject actinic keratoses</brief_summary>
	<brief_title>Multicenter , Double-blind , Placebo Controlled Comparing Test Fluorouracil Cream Carac Cream Actinic Keratosis</brief_title>
	<detailed_description>This multicenter , double-blind , vehicle-controlled , parallel group comparison study generic fluorouracil cream , 0.5 % Carac ( fluorouracil ) cream , 0.5 % subject actinic keratoses full face bald scalp .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Subject male and/or female , 18 year age old . Subject willing able give write informed consent . Subject willing able apply test article ( ) direct , comply study instruction commit followup visit duration study . Subject clinical diagnosis actinic keratoses least five ten clinically typical , visible palpable , discrete , AK lesion , least 4 mm diameter face ( exclude ear ) bald scalp . Subject good general health free disease state physical condition might impair evaluation AK lesion , investigator 's opinion , expose subject unacceptable risk study participation . Females must postmenopausal , surgically sterile , use effective method birth control negative urine pregnancy test ( UPT ) Baseline Visit Subject pregnant , lactate , plan become pregnant study . Subject currently enrol investigational drug device study . Subject use investigational drug investigational device treatment within 30 day prior Baseline Visit . Subject hyperkeratotic , hypertrophic , large matlike AKs ( e.g. , AK &gt; 1 cm2 size ) within Treatment Area . Subject need plan expose artificial tanning device excessive sunlight trial . Subject immunosuppressed ( e.g. , human immunodeficiency virus ( HIV ) , systemic malignancy , graft host disease , etc . ) Subject experience unsuccessful outcome previous topical fluorouracil therapy ( unsuccessful outcome define reasonable therapeutic trial compliance issue topical drug work ) . Subject history sensitivity ingredient test article . Subject know dihydropyrimidine dehydrogenase ( DPD ) enzyme deficiency . Subject use topical cream , lotion , gel kind within select Treatment Area within one day prior entry study . Subject use topical medication ; corticosteroid , alpha hydroxy acid ( e.g. , glycolic acid , lactic acid , etc . &gt; 5 % ) , beta hydroxy acid ( salicylic acid &gt; 2 % ) , urea &gt; 5 % , 5fluorouracil , diclofenac , imiquimod , ingenol mebutate , prescription retinoids ( e.g. , tazarotene , adapalene , tretinoin ) within select Treatment Area ( face bald scalp ) within one ( 1 ) month prior Baseline Visit . Subject cryodestruction , curettage , photodynamic therapy , surgical excision , treatment AK within select Treatment Area ( face bald scalp ) within one ( 1 ) month prior Baseline Visit . Subject use oral corticosteroid therapy , interferon , cytotoxic drug , immunomodulators , immunosuppressive therapy , retinoids within one month prior Baseline Visit . Subject dermatologic procedure surgery : laser resurfacing , Psoralen + ultraviolet A ( PUVA ) therapy , ultraviolet B therapy , chemical peel , dermabrasion within select Treatment area ( face bald scalp ) within six month prior Baseline Visit . Subject lesion suspicious skin cancer ( skin cancer rule biopsy ) untreated skin cancer within select Treatment Area ( face bald scalp ) . Subject skin pathology condition face bald scalp , investigator 's opinion , could interfere evaluation test article require use interfere topical , systemic , surgical therapy . Subject condition , investigator 's opinion , would make unsafe preclude subject 's ability fully participate research study . Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function , physical limitation . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator . Subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>